Damora Therapeutics Inc. (DMRA) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 51% of 52W Range • RSI-14 at 49.8 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DMRA currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.53) and Max Pain ($23.11) forces dealer call-delta covering toward $40.25.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Damora Therapeutics Inc. (DMRA) advanced +1.85% to $22.01, trading at 51% of its 52-week range ($4.95 – $38.33). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
U.S. stocks were mixed as the Dow gained 400 points. Winnebago jumped 7% on an EPS beat, while Super Micro and SpaceX rallied on strong outlooks.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DMRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DMRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Damora Therapeutics Inc. (DMRA) ranks #406 by composite RQD confidence (47/100, grade D) and #319 by equity capitalization ($1.36B). Within this direct 5-issuer industry benchmark cohort, DMRA leads on earnings valuation at N/A trailing P/E, while KRSA leads on capital efficiency and profitability with -5.7% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with DMRA at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DMRA
ACTIVE
Damora Therapeutics Inc. | D | 47/100 | — | — | -35.0% | +1.85% | $1.36B | Benchmark Subject |
| OMER Omeros Corporation | D | 46/100 | — | — | -35.0% | +5.98% | $1.37B | /omer-vs-dmra → |
| KRSA Korsana Biosciences Inc. | E | 33/100 | — | — | -5.7% | +0.37% | $1.38B | /krsa-vs-dmra → |
| KARD Kardigan Inc. | C- | 61/100 | — | — | — | +4.22% | $1.34B | /kard-vs-dmra → |
| NKTR Nektar Therapeutics | E | 33/100 | — | 96.0% | -35.0% | +1.63% | $1.34B | /nktr-vs-dmra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$209.8M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (+63.9% YoY). On the balance sheet, DMRA closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$209.8M | -$6.7M | -$6.7M | $260.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$21.4M | -$18.6M | -$18.6M | $17.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$38.3M | -$36.9M | -$36.9M | — | — |
As of 2026-11-01, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $22.01 (+1.85% 1D, market cap $1.36B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMRA ranks #406 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OMER (Omeros Corporation) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.37B) and KRSA (Korsana Biosciences Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -5.7%, cap $1.38B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while KRSA leads on capital efficiency (-5.7% ROIC).
Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $0 in revenue, -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DMRA last traded at $22.01 (+1.85% on volume of 460,322 shares), positioning the stock -6.46% below its 50-day simple moving average ($23.53) and -14.22% below its 200-day simple moving average ($25.66). Across its 52-week range of $4.95 to $38.33, DMRA sits at the 51.1% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($19.26 to $24.76).
Why DMRA Stock advanced +1.85% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.